Advaxis (ADXS) Price & Analysis

Q: What was Advaxis’s price range in the past 12 months?

Advaxis lowest stock price was <$0.01 and its highest was $0.80 in the past 12 months.

Q: What is Advaxis’s market cap?

Advaxis’s market cap is $20.55M.

Q: When is Advaxis’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Q: Is Advaxis overvalued?

According to Wall Street analysts Advaxis’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Advaxis pay dividends?

Advaxis does not currently pay dividends.

Q: What is Advaxis’s EPS estimate?

Advaxis’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Advaxis have?

Advaxis has 42,633,400 shares outstanding.

Q: Which hedge fund is a major shareholder of Advaxis?

Currently, no hedge funds are holding shares in ADXS

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Compare

838 Followers

ADXS Stock Chart & Stats

$0.64

$0.00(0.00%)

At close: Jan 07 4:00 PM EST

$0.64

$0.00(0.00%)

Day’s Range― - ―

52-Week Range<$0.01 - $0.80

Previous CloseN/A

Volume3.00

Average Volume (3M)1.61K

Market Cap

$20.55M

Enterprise Value$27.07M

Total Cash (Recent Filing)$4.88M

Total Debt (Recent Filing)$8.32M

Price to Earnings (P/E)―

Beta-3.05

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding42,633,400

10 Day Avg. Volume1,415

30 Day Avg. Volume1,607

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)-0.16

Price to Sales (P/S)307.38

P/FCF Ratio-0.14

Enterprise Value/Market Cap1.32

Enterprise Value/Revenue2.08K

Enterprise Value/Gross Profit-3.80

Enterprise Value/Ebitda-0.75

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Advaxis News

OS Therapies to acquire listeria programs from Ayala Pharmaceuticals

OS Therapies (OSTX) announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology...

1y ago

ADXS

OSTX

Advaxis Executive Reshuffle Following Asset Sale

Advaxis (ADXS) has provided an update. Ayala Pharmaceuticals, Inc. finalized a major asset sale on March 25, 2024,...

2y ago

ADXS

Immunome price target raised to $33 from $27 at Wedbush

Wedbush analyst David Nierengarten raised the firm’s price target on Immunome (IMNM) to $33 from $27 and keeps...

2y ago

ADXS

IMNM

Advaxis Enhances Operations Through Strategic Asset Sale

Advaxis (ADXS) has issued an update. Ayala Pharmaceuticals has sold a significant portion of its assets, specifically its...

2y ago

ADXS

Ayala Pharmaceuticals completes sale of AL102 to Immunome

Ayala Pharmaceuticals (ADXS) announced the completion of the previously announced sale of AL102, and related drug candidate AL101,...

2y ago

ADXS

IMNM

Advaxis Clarifies CMO Bonus Terms Amid Asset Sale

Advaxis (ADXS) has released an update. Ayala Pharmaceuticals, Inc. has agreed to sell most of its assets to...

2y ago

ADXS

Advaxis Asset Sale Approved by Majority Shareholder Vote

Advaxis (ADXS) has released an update to notify the public and investors about the submission of matters to...

2y ago

ADXS

Advaxis Executes Strategic Unregistered Equity Sales

Advaxis (ADXS) has released an update to notify the public and investors about the unregistered sales of equity...

2y ago

ADXS

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

2y ago

ADXS

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

2y ago

MOR

Advaxis Explores Future Post Asset Purchase Agreement

Advaxis (ADXS) has released an update to notify the public and investors about a regulation fd disclosure. The...

2y ago

ADXS

Advaxis Executives Secure Bonuses After Asset Purchase

Advaxis (ADXS) has released an update to notify the public and investors about its officers. The Compensation Committee...

2y ago

ADXS

Advaxis Announces Definitive Agreement with Ayala Pharmaceuticals

Advaxis (ADXS) has released an update to notify the public and investors about an entry into a material...

2y ago

ADXS

Immunome to acquire AL102 from Ayala for $20M in cash, $30M in stock

Immunome (IMNM) entered into a definitive asset purchase agreement with Ayala Pharmaceuticals (ADXS), a clinical-stage oncology company, to...

2y ago

ADXS

IMNM

ADXS FAQ

What was Advaxis’s price range in the past 12 months?

Advaxis lowest stock price was <$0.01 and its highest was $0.80 in the past 12 months.

What is Advaxis’s market cap?

Advaxis’s market cap is $20.55M.

When is Advaxis’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Advaxis’s earnings last quarter?

Currently, no data Available

Is Advaxis overvalued?

According to Wall Street analysts Advaxis’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Advaxis pay dividends?

Advaxis does not currently pay dividends.

What is Advaxis’s EPS estimate?

Advaxis’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Advaxis have?

Advaxis has 42,633,400 shares outstanding.

What happened to Advaxis’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Advaxis?

Currently, no hedge funds are holding shares in ADXS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Advaxis

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.